A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension

被引:0
|
作者
Godfrey, David A. [1 ]
Peplinski, Lee S. [2 ]
Stewart, Jeanette A. [3 ]
Stewart, William C. [3 ]
机构
[1] Glaucoma Associates Texas, Dallas, TX USA
[2] Kentuckiana Inst Eye Res, Louisville, KY USA
[3] PRN Pharmaceut Res Network LLC, 5001 LBJ Freeway,Suite 700, Dallas, TX 75244 USA
来源
CLINICAL OPHTHALMOLOGY | 2009年 / 3卷
关键词
comfort; travoprost BAK-free; latanoprost; glaucoma; ocular hypertension;
D O I
暂无
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To determine the short-term comfort after a single dose of travoprost BAK-free compared to latanoprost in primary open-angle glaucoma or ocular hypertensive patients. Design: Prospective, double-masked, randomized comparison of two separate active agents dosed once in opposite eyes. Methods: At Visit 1, qualified patients began a glaucoma medicine-free period for three days. At Visit 2, patients were randomly assigned to travoprost BAK-free or latanoprost in opposite eyes. Following dosing in each eye, patients completed a visual analog scale (VAS score, 0-100 mm) at specified time intervals and a comfort survey. Results: In 54 completed subjects, no difference existed five seconds after dosing, in comfort on the VAS between latanoprost (7.1 +/- 16.2 mm) and travoprost BAK-free (7.8 +/- 16.1 mm, P = 0.53). Also no differences existed between treatments following dosing for discomfort at individual timepoints past five seconds, peak discomfort or the time required to return to baseline comfort (P +/- 0.05). In addition, the comfort survey demonstrated no difference between products for burning, stinging, foreign body sensation, overall comfort and general acceptance between the products, both for absolute levels and changes from baseline (P +/- 0.05). Conclusion: Following a single instillation, both latanoprost and travoprost BAK-free exhibit similar comfort scores.
引用
收藏
页码:189 / 194
页数:6
相关论文
共 50 条
  • [31] The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension
    Stewart, WC
    Day, DG
    Stewart, JA
    Schuhr, J
    Latham, KE
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2001, 131 (05) : 631 - 635
  • [32] Double-Masked, Randomized, Multi-Center, Examination of Ocular Surface Disease in Glaucoma Patients on Latanoprost With Benzalkonium Chloride (BAK) versus Travoprost BAK-Free
    Katz, G. J.
    Springs, C. L.
    Craven, E. R.
    Montecchi-Palmer, M.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [33] Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
    Wang, Tsing Hong
    Aung, Tin
    Lu, Da-Wen
    George, Ronnie
    Senthil, Sirisha
    Lu, Fenghe
    Odani-Kawabata, Noriko
    Park, Ki Ho
    CLINICAL OPHTHALMOLOGY, 2024, 18 : 2093 - 2106
  • [34] A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension - A 12-week study
    Mishima, HK
    Masuda, K
    Kitazawa, Y
    Azuma, I
    Araie, M
    ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (08) : 929 - 932
  • [35] A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension
    Topouzis, F.
    Melamed, S.
    Danesh-Meyer, H.
    Wells, A. P.
    Kozobolis, V.
    Wieland, H.
    Andrew, R.
    Wells, D.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2007, 17 (02) : 183 - 190
  • [36] A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension
    Aung, T
    Chew, PTK
    Yip, CC
    Chan, YH
    See, JLS
    Khng, CC
    Hoh, ST
    Ng, LH
    Lee, HM
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2001, 131 (05) : 636 - 642
  • [37] A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study
    Walters, Thomas R.
    Kothe, Angela C.
    Boyer, Jose L.
    Usner, Dale W.
    Lopez, Krisol
    Duquesroix, Brigitte
    Fechtner, Robert D.
    Navratil, Tomas
    JOURNAL OF GLAUCOMA, 2022, 31 (06) : 382 - 391
  • [38] Comparison of the efficacy and safety of bimatoprost (0.03 %) and travoprost (0.004 %) in patients with primary open angle glaucoma
    Chander, A.
    Kapoor, H.
    Thomas, S.
    NEPALESE JOURNAL OF OPHTHALMOLOGY, 2013, 5 (01) : 75 - 80
  • [39] IOP-lowering efficacy and safety of travoprost compared to latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland, PA
    Landry, T
    Silver, LH
    Sullivan, EK
    Andrew, R
    Weiner, AL
    Bergamini, MVW
    Robertson, SM
    Mallick, S
    Davis, AA
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2001, 42 (04) : S556 - S556
  • [40] Long-term safety evaluation of latanoprost 0.005% without benzalkonium chloride in patients with open-angle glaucoma and ocular hypertension
    Lee, Bridgitte Shen
    Malhotra, Rajan
    Sall, Kenneth N.
    Ogundele, Abayomi
    Peace, James
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)